Highlights ABL Bio Inc.

Equities

A298380

KR7298380007

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
28,050 ^KRW	-0.36%		-2.77%	+14.02%

Jul. 11	ABL Bio Inc. announced that it has received KRW 139.999910884 billion in funding from Atinum Investment Co., Ltd, Company K Partners Limited and other investors	CI
Jul. 02	ABL Bio Inc. announced that it expects to receive KRW 139.999910884 billion in funding from Atinum Investment Co., Ltd, Company K Partners Limited and other investors	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	Jun. 10	MT
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	Mar. 25	CI
ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
ABL Bio Inc. Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease	22-01-11	CI
I-Mab and ABL Bio Inc. Jointly Announce Preclinical Data of Their 4-1Bb Bispecific Antibodies At the 2021 Society for Immunotherapy of Cancer Annual Meeting	21-11-12	CI
Compass Therapeutics, Inc. and ABL Bio Presented Clinical Trial Data for CTX-009	21-10-08	CI
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting	21-10-05	CI
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody	21-08-04	CI
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody	21-07-09	CI
I-Mab and ABL Bio Inc. Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors	21-04-06	CI
I-Mab and ABL Bio Inc. Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors	21-03-30	CI
HiFiBiO Therapeutics Announces Global Strategic Partnership with ABL Bio for the Co-Development of SARS-CoV-2 Neutralizing Antibody	20-09-14	CI
I-Mab and ABL Bio Inc. to Present Preclinical Data for Joint Bispecific	20-06-15	CI
Genscript Biologics Enters into an Agreement with ABL Bio Inc	19-11-18	CI
ABL Bio Inc. has completed an IPO in the amount of KRW 90 billion.	18-12-14	CI
TRIGR Therapeutics, Inc. and ABL Bio, Inc. Enters into Collaboration and License Agreement for TR009	18-12-03	CI
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies	18-11-28	CI
ABL Bio Inc. has filed an IPO.	18-09-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer